Abstracts tagged "biologic response modifiers and rituximab"

Abstract Number: 1755 • 2012 ACR/ARHP Annual Meeting
The Alternative ΔCD20 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue From Patients with Rheumatoid Arthritis
Clémentine Gamonet¹, Marina Deschamps², Béatrice Gaugler³, Philippe Saas⁴, Isabelle Auger⁵, Christophe Ferrand⁴, Eric Toussirot⁶ and CIC BT506⁷, ¹INSERM UMR1098/ Etablissement Français du Sang / Université de Franche Comté, France, ²INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, ³EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ⁴Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁵Université Aix Marseille II, INSERM UMR1097, Marseille, France, ⁶University Hospital, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁷Chru, Clinical Investigation Center Biotherapy 506, Besançon, France
Background/Purpose: determining predictive factors for response to biologics may help to select appropriate treatment in patients with RA. Rituximab (RTX) is a chimeric monoclonal antibody…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].